Jennifer G Gaultney

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. doi request reprint Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
    J G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Clin Pharm Ther 38:41-7. 2013
  2. doi request reprint Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 12:839-54. 2012
  3. doi request reprint Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Pharmacogenomics 12:411-21. 2011
  4. doi request reprint Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 47:1458-67. 2011
  5. ncbi request reprint Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Margreet G Franken
    Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands Electronic address
    Value Health 17:245-53. 2014
  6. doi request reprint Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands
    Margreet G Franken
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 49:8-16. 2013

Collaborators

Detail Information

Publications6

  1. doi request reprint Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
    J G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
    J Clin Pharm Ther 38:41-7. 2013
    ..Moreover, existing cost analyses were heavily based on conventionally treated patients. We investigated real-world health care costs of relapsed/refractory multiple myeloma in Dutch daily practice...
  2. doi request reprint Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 12:839-54. 2012
    ..Future economic evaluations will require an assessment of the cost-effectiveness of these agents in terms of sequence within the treatment paradigm and in combination with one another...
  3. doi request reprint Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
    Pharmacogenomics 12:411-21. 2011
    ..A cost-effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia...
  4. doi request reprint Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology
    Jennifer G Gaultney
    Institute for Medical Technology Assessment Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 47:1458-67. 2011
    ..To ensure access to and identification of high-quality studies, researchers conducting economic evaluations of future advances should strive towards evaluations that fulfil the Drummond criteria and are properly documented...
  5. ncbi request reprint Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Margreet G Franken
    Department of Health Policy and Management, Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands Electronic address
    Value Health 17:245-53. 2014
    ..We investigated whether outcomes research reduced policymaker uncertainty regarding the question whether the costs are worth public funding...
  6. doi request reprint Practical feasibility of outcomes research in oncology: lessons learned in assessing drug use and cost-effectiveness in The Netherlands
    Margreet G Franken
    Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands
    Eur J Cancer 49:8-16. 2013
    ..To investigate the practical feasibility to develop evidence on drug use and cost-effectiveness in oncology practice...